Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention
Authors' conclusion
D. welbionis abundance is influenced by metformin treatment and associated with prebiotic response, liver health and glucose metabolism in humans with obesity and diabetes. This study suggests that D. welbionis may play a role in metabolic health and warrants further investigation.
Study context
- Population
- Humans with obesity and T2D in the Food4Gut trial; mice with diet-induced obesity
- Participants
- 106 participants
- Comparison
- Metformin-treated vs untreated participants; prebiotic vs control; in mice, D. welbionis J115T and metformin alone or combined
Methodological detailsprebiotic intervention stratified by metformin treatment, quantitative PCR, in vitro growth study, in vivo mouse study
- Prebiotic intervention stratified by metformin treatment
- Quantitative PCR
- In vitro growth study
- In vivo mouse study
Primary result
As reported in the abstract
D. welbionis abundance
- D. welbionis abundance unaffected by prebiotic treatment
- D. welbionis abundance significantly higher in metformin-treated participants
- Prebiotic responders had higher baseline D. welbionis levels than non-responders
- D. welbionis negatively correlated with AST, ALT and fasting blood glucose
Further findings
In vitro effect of metformin on D. welbionis growth
- Metformin had no direct effect on D. welbionis growth
Metabolic variables in mice
- D. welbionis J115T reduced body weight gain and liver weight and improved glucose tolerance to a better level than metformin
- No synergistic effects of D. welbionis J115T with metformin
Original publication
Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention. Diabetologia. Published 28 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →